Sanofi: No pancreatitis problems for Lyxumia
According to Sanofi’s global diabetes chief, recent debate over concerns about an increased risk of pancreatic inflammation linked to the diabetes drug type GLP-1 will have an impact on the FDA’s view on the drug class.
by Stefan Singh Kailay
There have been a few indications about an increased risk of acute inflammation of the pancreas arising from the use of Sanofis diabetes drug Lyxumia, but the company is keeping a watchful eye out, Riccardo Perfetti, Vice President Medical Affairs, Global Division, in Sanofi tells Medwatch following recent studies and heavy debate about the class of diabetes drugs known as GLP-1s – a class that Lyxumia belongs to as well.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app
